<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972113</url>
  </required_header>
  <id_info>
    <org_study_id>611523 (Pro00000912)</org_study_id>
    <nct_id>NCT01972113</nct_id>
  </id_info>
  <brief_title>Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)</brief_title>
  <official_title>Vitamin K and Glucose Metabolism in Children at Risk for Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nattopharma ASA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The undercarboxylated fractions of the two vitamin K-dependent proteins osteocalcin and
      matrix Gla protein have been shown to play key roles in type 2 diabetes and cardiovascular
      disease (at least in mouse models). Clinical trials are needed to isolate the effects of
      vitamin K manipulation on carboxylation of these two proteins (osteocalcin and matrix GLA
      protein) and their subsequent effects on markers of diabetes and cardiovascular disease risk.
      The purpose of this pilot randomized, double-blind, placebo-controlled trial in children is
      to estimate the effective dose of vitamin K2 (menaquinone-7) supplementation (to improve
      carboxylation of both osteocalcin and matrix Gla protein), and whether it can have an effect
      on markers associated with diabetes and cardiovascular disease risk.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum lipid concentrations</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine if vitamin K supplementation improves fasting lipid panel (triglycerides, total cholesterol, HDL-cholesterol, and LDL-cholesterol) in a dose-dependent manner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine if vitamin K supplementation improves insulin sensitivity in a dose-dependent manner. Insulin sensitivity will be calculated from plasma insulin and glucose concentrations measured during a 2-hour glucose tolerance test by using the oral glucose minimal model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-cell function</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine if vitamin K supplementation improves insulin sensitivity in a dose-dependent manner. Beta-cell function, as assessed by dynamic beta-cell responsitivity, will be calculated from plasma glucose and C-peptide concentrations measured during a 2-hour glucose tolerance test by using the oral C-peptide minimal model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in coagulation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Coagulation-related parameters (i.e., prothrombin time and activated partial thromboplastin time) will be assessed at baseline and 8 weeks to assess clotting function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial stiffness (pulse wave velocity)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Arterial stiffness, as measured by pulse wave velocity (PWV), will be assessed at baseline and 8 weeks to explore whether change in arterial stiffness is influenced by vitamin K2 supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function (Flow-mediated dilation)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Endothelial function, as measured by flow-mediated dilation (FMD), will be assessed at baseline and 8 weeks to explore whether change in endothelial function is influenced by vitamin K2 supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of sex, race, bone age, and pubertal stage on changes in glucosemetabolism (insulin sensitivity and beta-cell function)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Moderation effects of sex, race, bone age, and pubertal stage in the associations of vitamin K-induced changes in carboxylation of osteocalcin on markers of glucose metabolism will be determined.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Prediabetes</condition>
  <condition>Dyslipidemia</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo-Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo-control group will take one placebo softgel capsules every day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose Vitamin K2 (45 mcg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Vitamin K2 (90 mcg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The high-dose vitamin K2 group will take one 90-mcg vitamin K2 softgel capsules every day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo-Control</intervention_name>
    <description>one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)</description>
    <arm_group_label>Placebo-Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)</intervention_name>
    <description>one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks</description>
    <arm_group_label>Low-Dose Vitamin K2 (45 mcg/d)</arm_group_label>
    <other_name>menaquinone-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)</intervention_name>
    <description>one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks</description>
    <arm_group_label>High-Dose Vitamin K2 (90 mcg/d)</arm_group_label>
    <other_name>menaquinone-7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 8 to 17 years

          -  BMI less than 85th percentile for age and gender

          -  Subject and parent/guardian understands the study protocol and agrees to comply with
             it

          -  Informed Consent Form signed by the parent/guardian and assent signed by the subject

        Exclusion Criteria:

          -  Subjects using vitamin supplements containing vitamin k

          -  Subjects with (a history of) metabolic or gastrointestinal diseases including hepatic
             disorders

          -  Subjects presenting chronic degenerative and/or inflammatory diseases

          -  Subjects receiving systemic treatment or topical treatment likely to interfere with
             evaluation of the study parameters (salicylates, antibiotics)

          -  Subjects receiving corticosteroid treatment

          -  Subjects using oral anticoagulants

          -  Subjects with a history of soy allergy

          -  Subjects who have participated in a clinical study more recently than one month before
             the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman K Pollock, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Medical College of Georgia, Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norman K Pollock, Ph.D.</last_name>
    <phone>706-721-5424</phone>
    <email>npollock@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celestine F Williams, M.S.</last_name>
    <phone>706-721-8553</phone>
    <email>cewilliams@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Georgia; Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norman K Pollock, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pollock NK, Bernard PJ, Gower BA, Gundberg CM, Wenger K, Misra S, Bassali RW, Davis CL. Lower uncarboxylated osteocalcin concentrations in children with prediabetes is associated with beta-cell function. J Clin Endocrinol Metab. 2011 Jul;96(7):E1092-9. doi: 10.1210/jc.2010-2731. Epub 2011 Apr 20.</citation>
    <PMID>21508147</PMID>
  </reference>
  <reference>
    <citation>Gower BA, Pollock NK, Casazza K, Clemens TL, Goree LL, Granger WM. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and Î²-cell function in overweight adults. J Clin Endocrinol Metab. 2013 Jul;98(7):E1173-80. doi: 10.1210/jc.2013-1203. Epub 2013 Apr 24. Erratum in: J Clin Endocrinol Metab. 2016 May;101(5):2265.</citation>
    <PMID>23616149</PMID>
  </reference>
  <reference>
    <citation>Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013 Jan;9(1):43-55. doi: 10.1038/nrendo.2012.201. Epub 2012 Nov 13. Review.</citation>
    <PMID>23147574</PMID>
  </reference>
  <reference>
    <citation>Pollock NK. Childhood obesity, bone development, and cardiometabolic risk factors. Mol Cell Endocrinol. 2015 Jul 15;410:52-63. doi: 10.1016/j.mce.2015.03.016. Epub 2015 Mar 27. Review.</citation>
    <PMID>25817542</PMID>
  </reference>
  <reference>
    <citation>Douthit MK, Fain ME, Nguyen JT, Williams CF, Jasti AH, Gutin B, Pollock NK. Phylloquinone Intake Is Associated with Cardiac Structure and Function in Adolescents. J Nutr. 2017 Aug 9. pii: jn253666. doi: 10.3945/jn.117.253666. [Epub ahead of print]</citation>
    <PMID>28794209</PMID>
  </reference>
  <reference>
    <citation>Fain ME, Kapuku GK, Paulson WD, Williams CF, Raed A, Dong Y, Knapen MHJ, Vermeer C, Pollock NK. Inactive Matrix Gla Protein, Arterial Stiffness, and Endothelial Function in African American Hemodialysis Patients. Am J Hypertens. 2018 May 7;31(6):735-741. doi: 10.1093/ajh/hpy049.</citation>
    <PMID>29635270</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Norman Pollock</investigator_full_name>
    <investigator_title>Associate Professor, Department of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Vitamin K</keyword>
  <keyword>Vitamin K2</keyword>
  <keyword>Menaquinone-7</keyword>
  <keyword>Osteocalcin</keyword>
  <keyword>Children</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Beta-cell function</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Matrix Gla protein</keyword>
  <keyword>Arterial stiffness</keyword>
  <keyword>Endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

